---
title: "EML4"
date: 2023-05-13 00:00:00
layout: post
categories: Gene
summary: "## Gene EML4"
tags: ['EML4', 'NSCLC', 'ALKinhibitors', 'Mutation', 'DrugResponse', 'Prognosis', 'CellMigration', 'MicrotubuleStability']
---

## Gene EML4

### Genetic Position
- Chromosome: 2
- Location: 2p21
- Gene type: Protein-coding

### Function
The EML4 (Echinoderm Microtubule-associated Protein-like 4) gene is known to play a role in promoting microtubule stability and is involved in cell migration and division.

### External IDs and Aliases
- HGNC ID: 13581
- NCBI Entrez ID: 27436
- Ensembl ID: ENSG00000124217
- OMIM ID: 608019
- UniProtKB/Swiss-Prot ID: Q9HC35
- Aliases: C2orf2, ROPP120, EMAPL4

### Mutations and Variations
- AA Mutation List: Some of the known amino acid mutations in EML4 gene are:
    * V274F
    * E329K
    * A349P
    * G362D
- Mutation Type: Missense mutations
- dbSNP IDs: rs3807989, rs77872630, rs34341415, rs76280259

### Somatic SNVs/InDels
- dbSNP IDs: rs12788290, rs62625016, rs143392990, rs756248187

### Related Disease
- Non-small cell lung cancer (NSCLC)

### Treatment and Prognosis
- EML4-ALK (anaplastic lymphoma kinase) fusion in NSCLC can be treated with ALK inhibitors like crizotinib, lorlatinib, etc.
- The EML4-ALK fusion is associated with a better prognosis in NSCLC compared to other types of lung cancer.

### Drug Response
- ALK inhibitors such as alectinib, brigatinib, ceritinib, crizotinib, etc., are highly effective against EML4-ALK fusion-positive NSCLC.

### Related Papers
- Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR. "Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer." Clinical Cancer Research. 2012 May 1;18(9):1472-82. DOI: [10.1158/1078-0432.CCR-11-2906]([Click](https://doi.org/10.1158/1078-0432.CCR-11-2906))
- Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, JÃ¤nne PA. "A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors." Cancer Research. 2011 Oct 1;71(19):6051-60. DOI: [10.1158/0008-5472.CAN-11-1340]([Click](https://doi.org/10.1158/0008-5472.CAN-11-1340))

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**